Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$8.9 million.

  • Biodesix's Free Cash Flow rose 1811.59% to -$8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.2 million, marking a year-over-year increase of 5313.21%. This contributed to the annual value of -$51.9 million for FY2024, which is 1330.01% down from last year.
  • Biodesix's Free Cash Flow amounted to -$8.9 million in Q3 2025, which was up 1811.59% from -$6.6 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Free Cash Flow ranged from a high of $809000.0 in Q2 2021 and a low of -$20.5 million during Q2 2024
  • Its 5-year average for Free Cash Flow is -$10.6 million, with a median of -$10.7 million in 2021.
  • In the last 5 years, Biodesix's Free Cash Flow skyrocketed by 11823.3% in 2021 and then plummeted by 132657.6% in 2022.
  • Biodesix's Free Cash Flow (Quarter) stood at -$10.7 million in 2021, then decreased by 29.37% to -$13.9 million in 2022, then dropped by 10.01% to -$15.3 million in 2023, then soared by 67.68% to -$4.9 million in 2024, then tumbled by 80.89% to -$8.9 million in 2025.
  • Its Free Cash Flow was -$8.9 million in Q3 2025, compared to -$6.6 million in Q2 2025 and -$8.7 million in Q1 2025.